Literature DB >> 12072155

Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells.

K Lemmer1, G Ahnert-Hilger, M Höpfner, S Hoegerle, S Faiss, P Grabowski, M Jockers-Scherübl, E O Riecken, M Zeitz, H Scherübl.   

Abstract

C-11- or F-18-DOPA positron emission tomography (DOPA PET) is a new sensitive imaging technique for small neuroendocrine gastrointestinal tumors which evaluates the decarboxylase activity. To further characterize the dopaminergic system in neuroendocrine gastrointestinal tumor cells, we investigated the expression of both dopamine receptors and the transmembrane dopamine transporter (DAT) in the human neuroendocrine pancreatic cell line BON and in the neuroendocrine gut cell line STC-1. Both BON and STC-1 cells expressed mRNA of the dopamine receptors D2-D5 and DAT. mRNA of the dopamine receptor D1 was detected in BON cells only. Both in BON and STC-1 cells, expression of D2 and D5 receptors and DAT was also demonstrated immunocytochemically. For functional receptor characterization intracellular cAMP levels ([cAMP]i) were determined. Whereas in STC-1 cells dopamine and the D1-like (D1/D5) receptor agonist SKF 38393 increased [cAMP]i, [cAMP]i was decreased by dopamine or the D2-like (D2-D4) receptor agonist quinpirole in BON cells. Functional DAT activity was, however, not detected in either cell line. The presence of both dopamine receptors and of the DAT suggests an autocrine and/or paracrine function of dopamine in neuroendocrine gastrointestinal tumor cells. Yet neither the transmembrane dopamine transporter nor dopamine receptors are likely to contribute to positive DOPA PET imaging of neuroendocrine gastrointestinal tumors. However, these molecules may be of diagnostic importance when applying other dopaminergic system tracers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072155     DOI: 10.1016/s0024-3205(02)01703-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study.

Authors:  Evanthia Diakatou; Gregory Kaltsas; Michail Tzivras; George Kanakis; Eugenia Papaliodi; George Kontogeorgos
Journal:  Endocr Pathol       Date:  2011-03       Impact factor: 3.943

2.  Effect of Gingerol on Cisplatin-Induced Pica Analogous to Emesis Via Modulating Expressions of Dopamine 2 Receptor, Dopamine Transporter and Tyrosine Hydroxylase in the Vomiting Model of Rats.

Authors:  Weibin Qian; Xinrui Cai; Yingying Wang; Xinying Zhang; Hongmin Zhao; Qiuhai Qian; Zhihong Yang; Zhantao Liu; Junichi Hasegawa
Journal:  Yonago Acta Med       Date:  2016-06-29       Impact factor: 1.641

3.  D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells.

Authors:  Biswarup Basu; Chandrani Sarkar; Debanjan Chakroborty; Subhalakshmi Ganguly; Saurav Shome; Partha Sarathi Dasgupta; Sujit Basu
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

4.  DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma.

Authors:  Li Li; Masaki Miyamoto; Yuma Ebihara; Seiji Mega; Ryo Takahashi; Ryunosuke Hase; Hiroyuki Kaneko; Masatoshi Kadoya; Tomoo Itoh; Toshiaki Shichinohe; Satoshi Hirano; Satoshi Kondo
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.352

5.  Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration.

Authors:  Jonathan Kipnis; Michal Cardon; Hila Avidan; Gil M Lewitus; Sharon Mordechay; Asya Rolls; Yael Shani; Michal Schwartz
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

6.  Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.

Authors:  Claudia Pivonello; Panagoula Rousaki; Mariarosaria Negri; Maddalena Sarnataro; Maria Napolitano; Federica Zito Marino; Roberta Patalano; Maria Cristina De Martino; Concetta Sciammarella; Antongiulio Faggiano; Gaetano Rocco; Renato Franco; Gregory A Kaltsas; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

7.  Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine?

Authors:  G Francia; M V Davì; E Montresor; C Colato; M Ferdeghini; V Lo Cascio
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 5.467

8.  PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells.

Authors:  Patrizia M Germano; Sandy N Lieu; Janjing Xue; Helen J Cooke; Fievos L Christofi; Yuxin Lu; Joseph R Pisegna
Journal:  J Mol Neurosci       Date:  2009-08-23       Impact factor: 3.444

9.  A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine.

Authors:  Michael Höpfner; Andreas P Sutter; Alexander Huether; Gudrun Ahnert-Hilger; Hans Scherübl
Journal:  BMC Cancer       Date:  2004-05-21       Impact factor: 4.430

10.  A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839).

Authors:  M Höpfner; A P Sutter; B Gerst; M Zeitz; H Scherübl
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.